Ipamorelin vs older secretagogues: what selectivity means

Growth hormone secretagogues spent their first decade as orphans: synthetic molecules that released growth hormone through a receptor with no known natural ligand. Then the ligand turned up in the stomach, and the field split into an older generation that pulls several hormonal strings at once and a newer one designed to pull exactly one. Ipamorelin is the second kind. The preparation on this page is Ipamorelin 5 mg. The evidence for the selectivity claim sits in three papers; the human record adds a fourth, and it is worth reading in that order.

The receptor finally got its natural ligand

Kojima and colleagues reported in Nature in 1999 that they had purified the endogenous ligand of the secretagogue receptor from rat stomach. They named it ghrelin, from the Proto-Indo-European root for growth. It is a peptide of 28 amino acids carrying an n-octanoyl group on its third serine, and that acyl chain is not decoration: without octanoylation at serine 3, the activity disappears. The acylated form releases growth hormone in vivo and in vitro. Human ghrelin differs from the rat form by two amino acids.

That paper redefined every synthetic secretagogue at a stroke. GHRP-6, GHRP-2 and their cousins were suddenly visible as mimics of a stomach hormone, acting through its receptor rather than through the hypothalamic releasing-hormone pathway. Tesamorelin, covered elsewhere on this site, works the other route entirely, which is why the two classes read so differently: the one GHRH analog with phase 3 data, in one population.

Ipamorelin was built by deleting the promiscuous core

Raun and colleagues described ipamorelin in 1998 as the outcome of a chemistry programme that started from GHRP-1 and removed its central Ala-Trp dipeptide. The result is a pentapeptide, and profiling with receptor antagonists confirmed it stimulates growth hormone release through the same GHRP-like receptor as GHRP-6.

Potency and efficacy came out comparable across three systems. On primary rat pituitary cells, ipamorelin released growth hormone with an EC50 of 1.3 against 2.2 nmol per litre for GHRP-6, at 85% of its maximal effect. In anaesthetised rats the ED50 values were 80 against 115 nmol per kg with higher maximal output for ipamorelin. In conscious swine the ED50 values were 2.3 against 3.9 nmol per kg at similar maxima. GHRP-2 in the same swine model showed higher potency but lower efficacy than either.

Then the selectivity result, which is the whole point of the molecule. None of the tested secretagogues moved FSH, LH, prolactin or TSH in swine. But GHRP-6 and GHRP-2 both raised ACTH and cortisol, while ipamorelin did not, matching the profile of growth-hormone-releasing hormone itself. Same growth hormone output, no stress-axis spillover. In animals, that is a clean separation.

The human record: one PK study, one null trial

Gobburu and colleagues ran ipamorelin in healthy volunteers in a dose-escalation design over five infusion rates with eight healthy men at each level, measuring both drug and growth hormone concentrations. The pharmacokinetics were dose-proportional with a short terminal half-life of 2 hours. Growth hormone responded as a single episode at every level, peaking at 0.67 hours and declining to negligible concentrations, with half-maximal stimulation at 214 nmol per litre.

That is a careful PK/PD model in healthy men. It is not the whole human file, and the part that is missing from it is the part that matters. One randomised trial in patients has been published, and it found nothing. Beck and colleagues ran a multicentre, double-blind, placebo-controlled phase 2 study in 117 adults recovering from small or large bowel resection, 114 of them in the safety and modified intent-to-treat populations. Treatment-emergent adverse events were reported in 87.5% of the ipamorelin arm and 94.8% of the placebo arm. The key endpoint was the time from the first dose to tolerance of a standardised solid meal: a median of 25.3 hours on ipamorelin against 32.6 on placebo, P = 0.15. The authors state it plainly — there were no significant differences between ipamorelin and placebo in the key or in the secondary efficacy analyses.

So the selectivity story above rests on animals, and the one patient study of the molecule has produced a null. What is still missing is a comparison in people: a PubMed search on 02.10.2026 for ipamorelin[tiab] AND GHRP-6[tiab] AND humans[mesh] returns 10 records, and not one of them is such a trial — they are analytical methods for detecting these peptides in urine, structure-activity and receptor-imaging papers, and reviews.

What the data do not show

A demonstrated human advantage for ipamorelin. The selectivity that defines the molecule was established in swine and rats, the human pharmacokinetics come from healthy volunteers, and the one randomised trial in patients — postoperative ileus, 114 analysed — ended with no significant difference between drug and placebo. Nor is there a head-to-head comparison against GHRP-2 or GHRP-6 in people. The older secretagogues have broader human records; ipamorelin has the cleaner animal profile and the thinner human file, and the single human efficacy test it has faced was negative. That asymmetry is the honest summary, and it runs in both directions.

What we supply

Ipamorelin 5 mg, alongside the GHRP-2 and GHRP-6 preparations discussed above, as supplied by the manufacturer, tracked, from inside the EU. Batch documentation for every product that carries any is explained in the COA guide linked from the product page.

Research use only. This page summarises published receptor pharmacology and human pharmacokinetics for research reference. It is not medical advice and not a suggestion for human use. Nothing we supply is for human or veterinary use.